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Introduction
Allergic manifestations are initiated by the aggregation of highaffinity IgE receptors (FceRI)' expressed on mast cells and basophils, when FceRI-bound IgE antibodies bind multivalent allergens (1) . FceRI are multichain-receptors composed of an IgE-binding a subunit, associated with a four-transmembrane domain /3 subunit and a homodimeric y subunit (2) . A consensus tyrosine-containing activation motif, in intracytoplasmic (IC) domains of FceRI/3 and y (3) , is thought to account for the cell-activating properties of FceRI (4) .
Mast cells (5, 6) and basophils (7, 8) also express lowaffinity IgG receptors (FcyR). Depending on their subtype, mouse mast cells express FcyRII and FcyRIII in variable proportions (6) . FcyRIII are multichain-receptors composed of a IgG-binding a subunit (9) , associated in mast cells with the same 3(10) and y ( 11) subunits as FceRIa. When aggregated by multivalent IgG immune complexes, FcyRIII also trigger the release of inflammatory mediators (12) and cytokines (13) . Under the same conditions, FcyRII do not (12, 13) . FcyRII are single-chain receptors which exist as two isoforms generated by alternative splicing of sequences of the first IC exon, FcyRIIbl and FcyRIIb2, which differ by a 47-amino acid insertion in the IC domain of FcyRIIbl (9) . Human basophils express FcyRII (8) , but no FcyRIII, and they failed to release histamine when challenged with anti-FcyRII (C. Lawrence and M. Daeron, unpublished data) . Ancient experiments aiming at demonstrating the ability of IgG immune complexes to trigger histamine release in human basophils were contradictory (14, 15) . Human FcyRII are of two types: FcyRIIA/C and FcyRIIB. FcyRIIA/C are single-chain receptors the IC domain of which possesses a tyrosine-containing activation motif (9) with cell-triggering capability (16) . FcyRIIB resemble closely murine FcyRII and they share a common IC aminoacid sequence (9) .
Evidence that FcR aggregation is a necessary and sufficient signal for triggering a cellular response (17) (18) (19) (20) was based on studies using multivalent ligands specific of a single FcR. Most cells, however, express several types of FcR and antibodies of more than one isotype are usually produced together against a given antigen. When antigen reaches FcERI-bound IgE antibodies on mast cells, it is therefore probably complexed to IgG antibodies, if IgG antibodies were generated against the same antigen. This is likely to occur during immunotherapy in allergic patients, when high titers of anti-allergen IgG antibodies have been raised (21) , but also during a normal immune response. Under these conditions, FceRI are therefore not only aggregated, they are also cross-linked to adjacent FcyR. In the present work, we examined the consequences of cross-linking FceRI to FcyRII on IgE-induced mast cell activation.
We found that, when cross-linked to FceRI, both FcyRII isoforms inhibit mediator and cytokine release triggered by FceRI aggregation and that inhibition depends on FcyRII intracytoplasmic sequences common to FcyRIIbl and b2. We showed that inhibition requires FceRI-FcyRII cross-linking, affects only crosslinked FceRI and is reversible. Our results provide a new hypothesis for the development of allergic manifestations and offer a possible mechanism for desensitization in allergic patients. Because mediator release could be abrogated in mast cells previously sensitized with IgE, they suggest new therapeutic approaches of allergic diseases.
Methods
Antibodies, antibody fragments, and antigens. Heteroconjugates made by chemically crosslinking Fab fragments of 2.4G2 and affinity-purified rabbit polyclonal anti-DNP antibodies (referred to as [2.4G2 x a-DNP] Fab2) were described previously (25) . (2.4G2 x a-DNP) Fab2 bind to FcyRII via the 2.4G2 Fab moiety and to dinitrophenyl conjugates via the anti-DNP Fab moiety. They were a generous gift of Dr. David M. Segal (NIH, Bethesda, MD).
Mouse IgE 14.205 Al, BSA (Sigma Chemical Co., St. Louis, MO) and ovalbumin (Sigma Chemical Co.) were dinitrophenylated using 2-,4-dinitrobenzene sulfonic acid (Eastman Kodak Co., Rochester, NY). After passage over Sephadex G25 (Pharmacia, Uppsala, Sweden), the average substitution numbers of dinitrophenylated proteins were 7.5 moles DNP/mole IgE, 13 moles DNP/mole BSA and 4 moles DNP/ mole ovalbumin. Rat IgE IR162 was biotinylated using the kit from Sigma Chemical Co. Streptavidin was from Pierce (Rockford, IL), Llysine and N-e-DNP-L-lysine from Sigma Chemical Co.
Cells. BMMC were prepared from BALB/c bone marrow cells as described (26) . They were maintained in culture in RPMI medium (Seromed, Biochrom A. G., Berlin, Germany) supplemented with 10% FCS, 100 IU/ml penicillin, 100 pLg/ml streptomycin, and 50% conditioned medium from WEHI-3 cells. P815 mouse mastocytoma cells and L929 cells were cultured in RPMI supplemented with 10% FCS, 100 IU/ml penicillin and 100,tg/ml streptomycin. RBL-2H3 cells (27) were cultured in DMEM supplemented with 10% FCS, 100 IU/ml penicillin and 100 ,ug/ml streptomycin. Only adherent RBL cells were used. They were recovered with trypsin-EDTA. Except RPMI, all culture reagents were from GIBCO BRL (Paisley, Scotland, UK).
Immunoprecipitation of iodine-labeled mast cells. BMMC or P815 cells were 1251I-labeled using lactoperoxydase. Membrane FcyR were precipitated with 2.4G2 and analyzed by SDS-PAGE under reducing conditions, before and after endoglycosidase-F (Bohringer Biochimica, Mannheim, Germany) treatment as previously described (6) . cDNA constructions and transfectants. RBL-2H3 cells stably transfected with cDNAs encoding murine FcyRIIbl (28) and FcyRIIb2 (29) , IC domain-deleted FcyRIIb2(IC1) (30), or chimeric FcyRII-ICIIIa ( 12) were described previously ( 12) . All transfectants used were cloned as described ( 12) . They were maintained in culture in the presence of 250 ,g/ml G418 (Geneticin; GIBCO BRL) and the expression of recombinant receptors on clones remained stable over the duration of experiments.
Immunofluorescence. Nontransfected and transfected RBL-2H3 cells were incubated for 1 h at 0C with 10 ,Lg/ml rat monoclonal IgE LO-DNP-30 or 2.4G2 mAb in HBSS containing 5% FCS, or with medium alone. Cells were washed and stained by being incubated for 30 min at 0C with 50 Mig/ml FITC-labeled MAR F(ab')2. Fluorescence was analyzed by flow cytometry using a FACScan (Becton-Dickinson, Mountain View, CA). Serotonin release. Transfected or nontransfected RBL-2H3 cells, resuspended in RPMI medium supplemented with 10% FCS at 1 X 106 cells/ml, were incubated at 370C for 1 h. with 2 ,uCi/ml [3H] serotonin (Amersham, Les Ulis, France), washed, resuspended in RPMI-FCS, incubated for another hour at 370C, washed again, resuspended in the same medium and distributed in 96-well microculture plates at 2 x 105 cells/well and incubated for 1 h at 37TC with IgE in a final volume of 50 jyd. Adherent cells were washed four times with 200 Ad HBSS (GIBCO BRL), 25 Mtl culture medium were added to each well and cells were warmed at 37°C for 15 min before challenge. Cells were challenged for 30 min at 37°C with 25 I-L of MAR F(ab')2, RAM F(ab')2, DNP-BSA or streptavidin, previously warmed at 37°C for 15 min. Reactions were stopped by adding 50 Ad ice-cold medium and by placing plates on ice. 50 Ald of supernatants were mixed with 200 pI Aqualuma-Plus scintillation fluid (Lumac, The Netherlands) and counted in a /-plate counter (Pharmacia, Uppsala, Sweden). The percentage of serotonin release was calculated using as 100% cpm contained in 50 41 harvested from wells containing the same number of cells that were lysed in 100,il of 0.5% SDS and 0.5% NP40.
BMMC were sensitized by an overnight incubation at 37°C with IgErich anti-ovalbumin immune serum before being loaded with [3H]serotonin under the same conditions as RBL cells. After washings and warming, cells were challenged for 10 min at 37°C with DNP-ovalbumin in Eppendorf tubes.
TNF release and assay. Aliquots of 7 X 105 RBL cells, previously sensitized by a 1-h incubation at 37°C with indicated concentrations of IgE, were resuspended in 150 j41 culture medium and incubated for 3 h at 37°C with 50 ,g/ml MAR F(ab')2 fragments. Cell-free supernatants were harvested and assayed for TNFa. TNFa was measured by a cytotoxic assay on the TNFa-sensitive L929 cells as described (13) . Briefly, 3 x 104 L929 cells were plated in each well of 96-well tissue culture plates. After a 20-h incubation at 37°C, culture medium was replaced by serial twofold dilutions of cell-free supernatants from stimulated cells. Supernatants were diluted in complete medium containing 1.5 ,ug/ml actinomycin D (Boehringer). After a 20-h incubation at 37°C, medium was removed, adherent cells were stained with 0.2% crystalviolet (Sigma Chemical Co.) in 1% ethanol for 15 min, wells were washed, dried, and the absorbance was measured at 570 nm using a Titerteck spectrophotometer (Labsystems, Helsinki, Finland).
Results
Inhibition of IgE-induced secretory responses by complexation of antigen to IgG antibodies in FcyRII-expressing mast cells. Bone marrow-derived mast cells (BMMC), sensitized with polyclonal IgE anti-ovalbumin (ova), released serotonin upon challenge with DNP-ova ( Fig. 1 a) . Nonsensitized BMMC did not release serotonin when challenged with DNP-ova or with DNP-ova complexed to monoclonal IgGl anti-DNP ( Fig. 1 a, open circles). DNP-ova-induced IgE-dependent serotonin release was found to decrease progressively if DNP-ova was complexed to increasing concentrations of IgGI anti-DNP ( Fig.  1 a, closed symbols). Inhibition was also observed when DNPova was complexed with dilutions of ascitic fluid of the same IgGI anti-DNP hybridoma (not shown). The same was ob- served in three other experiments of the same design, on BMMC sensitized with monoclonal IgE anti-DNP and challenged with DNP-BSA complexed to IgG1 anti-DNP (not shown). Antigen complexation to IgG antibodies therefore decreased IgE-mediated serotonin release by mouse mast cells. Low-affinity IgG receptors expressed by BMMC were immunoprecipitated by the rat anti-mouse FcyRII/HIl mAb 2.4G2 and examined by SDS-PAGE analysis before and after endoglycosidase-F treatment. Deglycosylated polypeptides with an apparent m.w. of 37, 32, and 28 kD were precipitated from the control mouse mastocytoma cells P815. They were previously identified as FcyRIIbl, FcyRIIb2, and FcyRIlla respectively (6, 31 ) . Confirming our previous results (6) , large amounts of FcyRI~bl were precipitated from BMMC, but only traces of FcyRIIb2 and Fc-yRllIa ( Fig. 1 b) . These results altogether raised the possibility that the crosslinking of FcyRLIbl to FceRI by immune complexes could inhibit IgE-induced mast cell activation and the subsequent secretory response.
Inhibition of IgE-induced secretory responses by cross-linking FceRI and FcyRII in RBL-2H3 transfectants. The latter hypothesis was tested using Rat Basophilic Leukemia cells (RBL-2H3) stably transfected with cDNAs encoding wild-type, deleted or chimeric murine FcyRII (Fig. 2 a) . The surface expression of murine FcyRlI and of endogenous FceRI was assessed by indirect immunofluorescence with 2.4G2 and with rat monoclonal IgE respectively (Fig. 2 b) . The expression of FcyRII was checked again, systematically, in all subsequent experiments. When sensitized with rat IgE, all transfectants released serotonin upon challenge with MAR F(ab')2 ( Fig.  3 ). When preincubated with 2.4G2 F(ab')2 fragments, no transfectant released serotonin above background upon challenge with MAR F(ab')2 ( Fig. 3 , open circles). The effect of cross-linking FcyRII to FceRI was searched for by studying serotonin release triggered by MAR F(ab') 2 in RBL transfectants sensitized with rat IgE, and incubated with increasing concentrations of F(ab')2 fragments of the rat mAb 2.4G2 (Fig. 3 , closed symbols). IgE-induced serotonin release was inhibited by crosslinking FceRI to FcyRIIbl (Fig. 3 domains of Fc-yRII and the IC domain of FcyRIIIa (FcyRII-ICHla, Fig. 3 d) . The same results were obtained in at least three experiments for each transfectant. They were repeated several times, with comparable results, in FcyRIIbl-, Fc-yRIIb2-, and Fc-yRII(ICl)-expressing cells obtained in at least one other independent transfection. Inhibition depends therefore on specific IC sequences common to FcyRIIbl and FcyRllb2.
FcyRIIb2-expressing transfectants, sensitized with rat IgE and challenged with MAR F(ab')2 for 3 h at 37°C, produced TNFa that could be quantitated by assaying cytotoxicity of cellfree supernatants on L929 cells. Cytotoxicity depended on the concentration of IgE used for sensitization ( Fig. 4 , open circles). It was markedly reduced if cells were incubated with 2.4G2 F(ab')2 before challenge with MAR F(ab')2 ( Fig. 4 , closed symbols). Like inhibition of serotonin release, inhibition of TNF production was proportional to the dilution of IgE used for sensitization. IgE-induced mediator release and cytokine production were therefore both inhibited by crosslinking FceRI to FcyRII.
Inhibition of IgE-induced mediator release requires FceRI-FcyRII cross-linking. In order to determine whether the decreased serotonin release might result from a change in the kinetics of the release process, FcyRIIb2-expressing cells were sensitized with rat IgE in the presence or absence of 2. F(ab')2 and challenged with MAR F(ab')2 for 15, 30, 45, or 60 min. Inhibition of serotonin release was of the same magnitude whatever the duration of challenge, when cells had been preincubated with 2.4G2 F(ab' )2 (data not shown). The crosslinking of FceRI to FcyRHI therefore did not slow down secretion but indeed decreased the amount of mediator released. In order to determine whether FcyRII occupancy would affect IgE-induced serotonin release, FcyRIIb2-expressing transfectants were incubated with or without 2.4G2 F(ab')2, sensitized with mouse IgE anti-DNP, and challenged with DNP-BSA. Serotonin release was of the same magnitude in cells preincubated or not with 2.4G2 F(ab')2 (data not shown). Ligand binding to FcyRII (binding of 2.4G2 was checked by indirect immunofluorescence) therefore had no inhibitory effect. To determine whether an independent FcyRII aggregation would affect IgE-induced serotonin release, FcyRIIb2-expressing transfectants were incubated with 2.4G2 F(ab ' )2 and sensitized with mouse IgE anti-DNP. They were washed, preincubated for various periods of time at 370C with MAR F(ab ')2, and finally challenged with DNP-BSA ( Fig. 5 ). Compared to cells not preincubated with MAR F(ab')2 (open symbols), serotonin release induced by DNP-BSA was unaffected in the presence of MAR F (ab' ) 2, whatever the duration of the preincubation with MAR F(ab')2 (closed symbols). The aggregation of FcyRH therefore had no effect on IgE-induced serotonin They were challenged with 50 ,g/ml MAR F(ab')2 for 3 h at 37°C. Cell-free supernatants were harvested and twofold dilutions were tested for cytotoxicity on L929 cells. The figure represents the percentage of cytotoxicity as a function of the dilution of supernatants. release, even if achieved 30 min before challenge with antigen. No effect on IgE-induced serotonin release was seen following an independent FcyRII aggregation in two other experiments.
In above experiments, FceRI were cross-linked to FcyRII by the same reagent that was used also for challenge (DNP-BSA or MAR F [ ab' ] 2, depending on the IgE). Under these conditions, FceRI-FcyRII cross-linking and FceRI aggregation were simultaneous. To dissociate the two events, FcyRIIb2-expressing transfectants were sensitized with a dinitrophenylated mouse monoclonal IgE, not directed against DNP, 14.205 Al, (DNP-mIgE) that could be subsequently cross-linked to FcyRII with heteroaggregates made of 2.4G2 Fab fragments and rabbit anti-DNP Fab fragments (referred to as [2.4G2 X a-DNP] Fab2), without being aggregated. Cells were then challenged with rat anti-mouse Ig (RAM) F(ab')2 to aggregate FceRI. Serotonin release induced by RAM F (ab' ) 2 was abolished, whatever the concentration of DNP-mIgE used for sensitization, if cells were preincubated with as little as 0.3 jig/ml (2.4G2 x a-DNP) Fab2 (Fig. 6 a) .
Nontransfected cells and transfectants expressing FcyRIIbl or FcyRII(ICl ) were sensitized by the same DNP-mIgE, incubated with or without (2.4G2 x a-DNP) Fab2, and challenged with RAM F(ab')2. When not exposed to (2.4G2 X a-DNP) Fab2, all three cells released serotonin upon challenge. Serotonin release was abolished if FcyRI~bl-expressing transfectants, but not FcyRII(ICI )-expressing transfectants or nontransfected cells, were preincubated with (2.4G2 X a-DNP) Fab2. Under the same conditions, (2.4G2 X a-DNP) Fab2 did not inhibit serotonin release by FcyRIIbl-expressing transfectants sensitized with the same IgE, but not dinitrophenylated (Fig. 6 b) . Identical results were seen in at least three experiments of the same design performed with each transfectant. FceRI-FcyRll crosslinking, prior to FcERI aggregation, therefore abrogated subsequent serotonin release.
Inhibition reversibly affects only FceRI cross-linked to FcyRII. The possibility to dissociate FceRI-FcyRII crosslinking from FcERI aggregation enabled to examine whether inhibition would affect only crosslinked FceRI or whether it would affect also other FceRI. This was achieved by sensitizing mast cells with two types of IgE which could be cross-linked to FcyRII or aggregated independently. When sensitized with dinitrophenylated mouse IgE 14.205 Al (DNP-mIgE), FcyRIIb2-expressing transfectants released serotonin upon challenge with RAM F(ab' )2 ( Fig. 7 a, open circles) , but not with streptavidin (not shown). Serotonin release was inhibited if cells were preincubated with (2.4G2 X a-DNP) Fab2 (Fig. 7 a, closed circles) .
When sensitized with biotinylated rat IgE IR162 (Biot-rIgE), FcyRIIb2-expressing transfectants released serotonin upon challenge with streptavidin ( Fig. 7 b, open circles), but not with RAM F(ab')2 (not shown). Serotonin release was not affected if cells were preincubated with (2.4G2 X a-DNP) Fab2 (Fig. 7 b, closed circles) . When sensitized with a mixture of DNP-mIgE and Biot-rIgE, FcyRIlb2-expressing transfectants released serotonin upon challenge with either RAM F(ab')2 or streptavidin, and a dose-dependent competition between the two IgE used for sensitization could be seen (Fig. 7 c -f open circles). Serotonin release induced by RAM F(ab')2 ( Fig. 7 c and e, closed circles), but not serotonin release induced by streptavidin ( Fig. 7 d, and f closed circles) , was abolished if cells were incubated with (2.4G2 X a-DNP) Fab2 prior to challenge. It follows that inhibition was restricted to FcERI crosslinked to FcyRll and left non-cross-linked FceRI fully capable of triggering mediator release upon aggregation. The same conclusion could be drawn from two additional experiments of the same design performed with the same reagents.
Finally, we wondered whether inhibition observed upon FceRI-FcyRll cross-linking would be reversed upon crosslinking disengagement in the presence of an excess of monovalent hapten. FcyRIIb2-expressing transfectants were sensitized with dinitrophenylated mouse IgE 14.205 Al (DNP-mIgE) that was subsequently cross-linked or not cross-linked to FcyRllb2 with (2.4G2 X a-DNP) Fab2, as in above experiments. Cells were then incubated for increasing periods of time at 37°C with an excess of DNP-lysine or, as a negative control, of lysine, before they were challenged with RAM F(ab')2. As expected, serotonin release was inhibited when cells not exposed to hapten were incubated with (2.4G2 X a-DNP) Fab2 (Fig. 8 , open circles). DNP-lysine (black circles) had no effect on serotonin release induced by the aggregation of DNP-mIgE not crosslinked to FcyRHb2 (broken line), but it reduced by 50% inhibition of serotonin release induced by aggregating DNP-mIgE crosslinked to FcyRIIb2 (solid line). The same molar concentration of lysine (grey circles) had no effect on inhibition (solid line). Comparable results were obtained in two other experiments. This indicates that FcERI whose triggering ability was previously abolished recovered from inhibition upon cross-linking disengagement. Inhibition therefore is reversible and requires that FceRI-FcyRH cross-linking be maintained.
Discussion
Our results demonstrate that mast cell activation via high-affinity receptors for IgE may be controlled by low-affinity receptors for IgG. This control was effective whenever FceRI were crosslinked to FcyRII with an intact IC domain, irrespectively of the cross-linking ligand. It required FceRI-FcyRII cross-linking, affected only FceRI crosslinked to FcyRll and was reversible upon cross-linking disengagement. Such a regulation might be of physiological and of clinical relevance.
Inhibition was observed in RBL transfectants, when endogeneous rat FceRI were cross-linked to recombinant murine FcyRIIbl or to FcyRIb2. Inhibition was not due to a competition between IgE and 2.4G2 for MAR F(ab' )2 or to extracellular steric hindrance for the following two reasons: (a) the MAR F(ab')2 concentration used for crosslinking IgE and 2.4G2 F(ab')2 was 25-fold higher than the concentration sufficient RBL-FCRiib2 After being washed, cells were incubated for 1 h at 37°C with indicated concentrations of (2.4G2 x a-DNP) Fab2, washed again, and challenged with 50 pHg/ml RAM F(ab')2 for 30 min.
for triggering an optimal serotonin release upon aggregation of IgE, and comparable inhibitions were seen when 50, 25 or 12.5 ig/ml MAR F(ab')2 were used for challenge (data not shown); (b) Inhibition was not seen in cells expressing FcyRII deletants lacking IC domain, which bound comparable amounts of 2.4G2 F(ab')2 fragments as wild-type FcyRII as judged by immunofluorescence with FITC-conjugated MAR F(ab')2. Steric hindrance of IC domains could neither account for inhibition because it was not seen in transfectants expressing chimeric receptors having the extracellular and transmembrane domains of FcyRII and the IC domain of FcyRIlla. Inhibition therefore depends on specific IC sequences shared by FcyRIIbl and FczyRIIb2. Murine FcyRII have been known for long to inhibit B cell activation triggered by B cell receptor (BCR) aggregation, and IC sequences required for FcyRII to inhibit BCRmediated B cell activation have recently been identified (32, 33) . Whether the same FcyRII IC sequences are responsible for FcyRII-mediated inhibition of IgE-induced mast cell activation is currently under study. BCR, like FceRI and FcyRIII, is composed of a ligand-binding subunit, associated with two subunits whose IC domains possess consensus tyrosine-con-taining activation motifs similar to those of FceRIy and p (34) , and it may be a general property of FcyRII to regulate tyrosinecontaining activation motif-dependent cell activation. Inhibition affected secretory responses of mast cells as different as the release of preformed mediators and the de novo synthesis of cytokines. It is therefore susceptible to control both the initiation of allergic reactions and the late phase reaction in which cytokines play a major role (35) . Inhibition, however was not the consequence of a general desensitization of mast cells since non-cross-linked receptors could function normally and triggered serotonin release upon aggregation while crosslinked receptors could not. Inhibition was not an all-or-nothing phenomenon. Experiments on FcyRIIb2-expressing transfectants incubated with lower concentrations of 2.4G2 F(ab')2 than those used in Fig. 3 showed a clearcut dose-dependent inhibition (not shown). Inhibition required the crosslinking of FceRI to FcyRll. MAR F(ab') 2 could indeed crosslink rat IgE LO-DNP-30 and rat 2.4G2 F(ab')2 inasmuch as (a) the same MAR F(ab')2 conjugated to FITC bound to both rat reagents in indirect immunofluorescence experiments (see gered serotonin release and TNF secretion by RBL cells sensitized with rat IgE (this manuscript) and by transfectants expressing FcyRHI preincubated with 2.4G2 F(ab')2 (12, 13) . Neither FcyRLI occupancy by 2.4G2 F(ab')2 nor FcyRll aggregation by 2.4G2 F(ab ' )2 and MAR F(ab ')2, by themselves, affected serotonin release. This was confirmed with (2.4G2 X a-DNP) Fab2 which had no effect when bound only to FcyRII (in FcyRIIb 1-expressing cells sensitized with nondinitrophenylated IgE), or to IgE only (in nontransfected cells sensitized with DNP-IgE), but abolished serotonin release when cross-linking IgE to FcyRll with an intact IC domain (in FcyRIIbland FcyRIIb2-, but not in FcyRII(ICI )-expressing cells, sensitized with DNP-IgE). Moreover, inhibition could be reversed when DNP-mIgE previously cross-linked to FcyRII by (2.4G2 X a-DNP) Fab2 were disengaged from cross-linking with monovalent DNP-Lysine. One may notice that a prolonged exposure to DNP-Lysine was required for inhibition to be reduced. Whether this reflects a low dissociation rate of multiple interactions between (2.4G2 x a-DNP) Fab2 and DNP7.5-mIgE or whether FcERI required time to recover from cross-linking is not known. We are currently investigating the intracellular consequences of receptor cross-linking.
Inhibition was not seen only in RBL transfectants, when recombinant murine FcyRII were artificially cross-linked to rat FceRI with monoclonal anti-FcyR antibodies and MAR F(ab ')2 or with (2.4G2 x a-DNP) Fab2 heteroaggregates. IgEinduced serotonin release was also inhibited in nontransformed mast cells, which express constitutive FcyRII, sensitized with polyclonal serum IgE, when receptor cross-linking was achieved by IgG immune complexes. To rule out a possible competition of antibodies for the same epitope, we used IgE and IgG antibodies of different specificities. The complexation of DNP-BSA to IgGI anti-DNP mAb also inhibited the release of serotonin by BMMC sensitized with mouse monoclonal IgE anti-DNP, as well as the production of TNFa by the murine mastocytoma cells MC9 sensitized with IgE anti-DNP (data not shown). Under these conditions, competition between IgG and IgE antibodies for the same epitopes cannot be excluded. An inhibitory effect of FcyRII, rather than a competition for antigen or an extracellular steric hindrance, however, was strongly suggested by the finding that inhibition of the TNF response was abolished if MC9 cells were preincubated with with 2.4G2 F(ab') 2 before challenge with immune complexes (data not shown). 2.4G2 F(ab')2, indeed, block the Fc-binding site of FcyRII (24) . Immune complex-induced inhibition mimics physiologic conditions, when IgG antibodies directed against identical or different epitopes of the same antigen as IgE antibodies interact with FcyRll by their Fc portions, while antigen binds FceRI-bound IgE on the same cell. A reasonable hypothesis would be that, during the course of a normal immune response, physiologic IgE-mediated mast cell activation might occur in the presence of antigen, which would be normally maintained at low levels by IgG antibodies bound to the same antigen, so that no sign of hypersensitivity is detectable. If so, one can speculate that allergic manifestations might arise when, for any reason, this control is not efficient enough. This also reminds the situation when allergic patients are treated by the injection of increasing amounts of allergen. Such an immunotherapy is usually successful after high titers of IgG antibodies have been induced against allergen (21), but no satisfactory mechanism was yet proposed. Human FcyRIIB are the human equivalent of murine FcyRII, and they were recently reported to inhibit murine B cell activation (36). One might therefore expect that FcyRIIB could be capable of regulating FceRI in human basophils. If so, inhibition described here might not only explain the success of desensitization, it might also explain its relative inefficacy. When FceRI aggregation and crosslinking to FcyRII were simultaneously produced by MAR F(ab')2 reacting with FcyRII-bound 2.4G2 F(ab')2 and FceRI-bound rat IgE, or by antigen-IgG immune complexes, inhibition was partial and inversely proportional to the concentration of IgE used for sensitization. Under these conditions, one cannot prevent adjacent IgE molecules from being aggregated without being cross-linked to 2.4G2, and chances of IgE aggregation can be expected to increase with the density of IgE at the cell surface.
It was recently reported that asthmatic patients injected with IgG immune complexes made with allergen and affinity-purified anti-allergen IgG antibodies had markedly reduced symptoms (37, 38) . The mechanism of this effect was not investigated and we propose the inhibition described here as a likely explanation. This suggests that manoeuvres aiming at crosslinking FceRI to FcyRI might be successful for controlling hypersensitivity manifestations in allergic patients. One advantage of FcyRll-mediated inhibition of IgE-induced mast cell activation, in terms of therapeutics, is that it can operate after mast cells were already sensitized with IgE, as it is the case in allergic patients. Our model where DNP-IgE are crosslinked to FcyRII by (2.4G2 X a-DNP) Fab2, simulates such a therapeutic approach. Under these conditions, the inhibitory effect was deep enough for enabling less than 1 jLg/ml (2.4G2 X a-DNP) Fab2 to abolish serotonin release triggered by 50 ,ig/ml MAR F(ab ' )2 in RBL cells sensitized with 10 jtg/ml IgE. The higher efficacy of bispecific heteroaggregates in inhibiting IgE-induced serotonin release, compared with that of 2.4G2 F(ab')2 and MAR F(ab' )2, may be explained because the preincubation of transfectants with (2.4G2 x a-DNP) Fab2 enabled FceRI to be cross-linked to FcyRII before FceRI-bound IgE were aggregated by RAM F(ab' )2. Appropriate ligands capable to reproduce the same cross-linking in humans are currently under investigation.
